Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13G Cidara Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Centessa Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Protara Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Aeva Technologies, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Mereo BioPharma Group Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.
-
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approv
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-
Medincell Announces Successful c.€43 Million Global Offering
-
Solid Biosciences (SLDB) Prices 35.74M Share Offering at $4.03/sh
-
Solid Biosciences Announces Pricing of Underwritten Offering
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Dec 31
-
Form 13F-NT Adage Capital Management For: Dec 31
-
Form SCHEDULE 13G ProQR Therapeutics N.V. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Monopar Therapeutics Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A VERU INC. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SCHEDULE 13G/A Sable Offshore Corp. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SCHEDULE 13G/A Nkarta, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SCHEDULE 13G/A Syros Pharmaceuticals, Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SCHEDULE 13G/A Compass Therapeutics, Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SCHEDULE 13G/A TScan Therapeutics, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SCHEDULE 13G Karyopharm Therapeutics Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Mereo BioPharma Group Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A enGene Holdings Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SCHEDULE 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Dynamix Corp Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Aligos Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G ZEVRA THERAPEUTICS, INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Shattuck Labs, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SCHEDULE 13G Aclaris Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Seadrill Ltd Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Protara Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Sitio Royalties Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Janux Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Tectonic Therapeutic (TECX) Announces $185M Private Placement
-
Tectonic Announces $185 Million Private Placement
-
Form D/A Adage Capital Partners,
-
ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
-
The Crown Publishing Group partners with Storehouse In A Box to launch Storehouse Voices™, a new imprint committed to elevating Black voices
-
Monopar Therapeutics (MNPR) Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
-
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
-
Trevi Therapeutics (TRVI) Prices 12.5M Share Offering at $4/sh

